Genome Surgery Is Coming, Says Scientist
Researchers from Columbia University have developed a new technique for the powerful gene editing tool CRISPR to restore retinal function in mice afflicted by a degenerative retinal disease, retinitis pigmentosa.
This is the first time researchers have successfully applied CRISPR technology to a type of inherited disease known as a dominant disorder. This same tool might work in hundreds of diseases, including Huntington’s disease, Marfan syndrome, and corneal dystrophies.
In the study, published in Ophthalmology, Dr. Stephen H. Tsang, PhD, and his colleagues sought to create a more responsive CRISPR tool so it can treat more patients, regardless of their individual genetic profile.
“Genome surgery is coming,” Dr. Tsang said in a press release. “Ophthalmology will be the first to see genome surgery before the rest of medicine.”
Dr. Tsang has referred to the technique as genome surgery since it cuts out the bad gene and replaces it with a normal, functional gene. The team anticipates human trials to begin in three years.
Historically, autosomal dominant retinitis pigmentosa and other similar diseases have presented a unique challenge to researchers because only one copy of a mutated gene is inherited from an individual’s parents, and the individual has one normal gene on a pair of autosomal chromosomes. The challenge lies in the desire to edit only the mutant copy of a gene without affecting the healthy one.
A strategy, however, designed by Dr. Tsang and colleagues could potentially cut out the old gene and replace it with a good gene, without affecting its normal function. The “ablate-and-replace” strategy can be used to develop CRISPR toolsets for all types of mutations that reside in the same gene and is not exclusive for a type of mutation.
After the subretinal injection of combination ablate-and-replace gene therapy, the thickness of the outer nuclear layer (ONL) was approximately 17% to 36% more than the ONL thickness resulting from gene replacement-only therapy at 3 months after adeno-associated virus (AAV) injection. Additionally, electroretinography results exhibited that the a and b waves of both RhoP23H and RhoD190N disease models were preserved more significantly using ablate-and-replace gene therapy (P<0.001), but not by gene replacement monotherapy.
“As a proof of concept, our results suggest that the ablate-and-replace strategy can ameliorate disease progression as measured by photoreceptor structure and function for both of the human mutation knock-in models,” Dr. Tsang concludes.
“These results demonstrate the potency of the ablate-and-replace strategy to treat RP caused by different Rho mutations. Furthermore, because ablate-and-replace treatment is mutation independent, this strategy may be used to treat a wide array of dominant diseases in ophthalmology and other fields.”
It is expected that clinical trials using this strategy for gene therapy would permit researchers to determine if this any benefit is provided for patients with diseases of interest.